- Home
- LNC vs ABVX Comparison
LNC vs ABVX Comparison
Compare LNC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LNC | ABVX |
|---|---|---|
| Founded | 1905 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Life Insurance | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 10.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LNC | ABVX |
|---|---|---|
| Price | $32.56 | $117.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 12 |
| Target Price | $44.86 | ★ $128.42 |
| AVG Volume (30 Days) | ★ 2.5M | 698.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $3.77 | $0.22 |
| P/E Ratio | $7.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.58 | $4.77 |
| 52 Week High | $46.82 | $148.83 |
Technical Indicators
Market Signals| Indicator | LNC | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 28.82 | 48.81 |
| Support Level | N/A | $106.37 |
| Resistance Level | $35.62 | $131.27 |
| Average True Range (ATR) | 1.53 | 5.21 |
| MACD | -0.19 | -0.67 |
| Stochastic Oscillator | 5.35 | 41.53 |
Price Performance
Historical ComparisonAbout LNC Lincoln National Corporation
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.